福利姬液液酱喷水,国产成人av网站网址,亚洲欧美日产综合在线网,无码H黄肉动漫在线观看网站

美國Tau Therapeutics
研發(fā)的T型鈣通道阻滯劑米貝拉地爾（mibefradil）用于實體腫瘤的治療。

Tau Therapeutics is developing oncology drugs for solid tumors that selectively inhibit the T-type calcium channel. The company’s approach, called Interlaced Therapy?, capitalizes on the central role of calcium influx through T-type calcium channels during cancer cell growth. T-type calcium channel blockade with Tau’s drugs arrests tumor cells at their most vulnerable metabolic point in the cell cycle, uniquely amplifying the effects of conventional therapies and overcoming drug resistance.

Tau’s first product, mibefradil, has been used extensively in humans and its safety profile is well known. Mibefradil is now entering clinical trials for brain cancer with support from the NCI.

Tau Therapeutics is a private company based in Charlottesville, VA.